Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings PharmaCorp Rx Inc.: Strengths and Weaknesses

Highlights: PharmaCorp Rx Inc.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: PharmaCorp Rx Inc.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

PharmaCorp Rx Inc. SectorCanada

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

-

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

PharmaCorp Rx Inc. SectorCanada

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

PharmaCorp Rx Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

PharmaCorp Rx Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

-

Rating Revisions

PharmaCorp Rx Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
64.61M - - - -
15.14B
AA
6.93B
AA
6.13B
AAA
3.73B
AAA
3.25B
AAA
3.15B
BBB
3.12B
BB
2.57B -
BBB
- -
2.53B - - - - -
Average 4.66B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PCRX Stock
  4. Ratings PharmaCorp Rx Inc.